Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Excyte Biopharma Ltd.
First patient dosed in YK012 trial-the world's first TCE therapy for primary membranous nephropathy
May 29, 2025
From
Excyte Biopharma Ltd.
Via
ACN Newswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.